Inventor · disambiguated record
Carsten Terjung
Also filed as: TERJUNG CARSTEN
13 granted patents·15 pending applications·40 citations·filing 2014–2024
87Inventor score
Top patents by PatentIndex Score
28 records- 0194US10022453B2Antibody drug conjugates (ADCs) with kinesin spindel protein (KSP)Bayer Pharma AG·Filed 2014·Granted Jul 17, 2018·16 cites·39 claims
- 0292US11123439B2Antibody drug conjugates (ADCS) and antibody prodrug conjugates (APDCS) with enzymatically cleavable groupsBayer Pharma AG·Filed 2016·Granted Sep 21, 2021·8 cites·51 claims
- 0389US10485880B2Antibody-drug conjugates (ADCs) of KSP inhibitors with aglycosylated anti-TWEAKR antibodiesBayer Pharma AG·Filed 2015·Granted Nov 26, 2019·11 cites·29 claims
- 0487US11685714B2Prodrugs of cytotoxic active agents having enzymatically cleavable groupsBayer Pharma AG·Filed 2017·Granted Jun 27, 2023·3 cites·30 claims
- 0580US2025099600A1Active Metabolites of Kinesin Spindle Protein Inhibitor ConjugatesBayer Pharma AG·Filed 2024·Application pending·0 cites
- 0675US10722501B2Substituted 5,6,7,8-tetrahydro[1,2,4]triazolo[4,3-A]pyridine-3(2H)-ones and 2,5,6,7-tetrahydro-3H-pyrrolo[2,1-C][1,2,4]triazol-3-ones, and use thereofBAYER AG·Filed 2017·Granted Jul 28, 2020·2 cites·19 claims
- 0771US12503491B2MASP inhibitory compounds and uses thereofBAYER AG·Filed 2023·Granted Dec 23, 2025·0 cites·8 claims
- 0870US2024043379A1Prodrugs of cytotoxic active agents having enzymatically cleavable groupsBayer Pharma AG·Filed 2023·Application pending·0 cites
- 0968US12144865B2Antibody drug conjugates with enzymatically cleavable groupsBayer Pharma AG·Filed 2021·Granted Nov 19, 2024·0 cites·33 claims
- 1064US2023346777A1Use of sgc activators for the treatment of ophthalmologic diseasesBAYER AG·Filed 2023·Application pending·0 cites
- 1162US11667675B2MASP inhibitory compounds and uses thereofBAYER AG·Filed 2020·Granted Jun 6, 2023·0 cites·3 claims
- 1259US2022241273A1Use of sgc activators for the treatment of ophthalmologic diseasesBAYER AG·Filed 2022·Application pending·0 cites
- 1356US2023382904A1SUBSTITUTED 4-([1,2,4]TRIAZOLO[1,5-a]PYRIDIN-6-YL)THIOPHENE-2-CARBOXAMIDE DERIVATIVES AND USE THEREOFUNIV JOHNS HOPKINS·Filed 2021·Application pending·0 cites
- 1454US2023270729A1Use of n-phenylacetamides having p2x4 receptor antagonistic activity for treating certian ocular disordersBAYER AG·Filed 2021·Application pending·0 cites
- 1552US10479765B2Substituted N,2-diarylquinoline-4-carboxamides and the use thereof as anti-inflammatory agentsBayer Pharma AG·Filed 2018·Granted Nov 19, 2019·0 cites·10 claims
- 1650US2023086702A1Substituted 2-amino-pyrazolyl-[1,2,4]triazolo[1,5a]pyridine derivatives and use thereofUNIV JOHNS HOPKINS·Filed 2020·Application pending·0 cites
- 1745US2016222056A1Substituted phenylalanine derivativesBayer Pharma AG·Filed 2014·Application pending·0 cites
- 1845US2016280688A1Substituted phenylalanine derivativesBayer Pharma AG·Filed 2014·Application pending·0 cites
- 1945US2016237067A1Substituted phenylalanine derivativesBayer Pharma AG·Filed 2014·Application pending·0 cites
- 2045US2016237045A1Substituted phenylalanine derivativesBayer Pharma AG·Filed 2014·Application pending·0 cites
- 2145US2016244437A1Substituted phenylalanine derivativesBayer Pharma AG·Filed 2014·Application pending·0 cites
- 2245US2016280699A1Substituted phenylalanine derivativesBayer Pharma AG·Filed 2014·Application pending·0 cites
- 2345US2016237044A1Substituted phenylalanine derivativesBayer Pharma AG·Filed 2014·Application pending·0 cites
- 2443US10189788B2Substituted N,2-diarylquinoline-4-carboxamides and the use thereof as anti-inflammatory agentsBayer Pharma AG·Filed 2015·Granted Jan 29, 2019·0 cites·11 claims
- 2542US2016272617A1Substituted phenylalanine derivativesBayer Pharma AG·Filed 2014·Application pending·0 cites
- 2639US11136296B2Substituted N-arylethyl-2-arylquinoline-4-carboxamides and use thereofBAYER AG·Filed 2018·Granted Oct 5, 2021·0 cites·13 claims
- 2738US11337973B2Substituted [1,2,4]triazolo[4,3-A]pyrazines as prolyl endopeptidase inhibitorsBAYER AG·Filed 2018·Granted May 24, 2022·0 cites·31 claims
- 2836US10117864B2Substituted N-bicyclo-2-aryl-quinolin-4-carboxamides and use thereofBayer Pharma AG·Filed 2016·Granted Nov 6, 2018·0 cites·20 claims
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →